AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback